Neoplasm
Not yet recruitingStudy on Pembrolizumab, Atezolizumab, and Nivolumab with Carbon Ion Radiotherapy for Patients with Advanced Melanoma, Urothelial Carcinoma, NSCLC, or Head & Neck Cancer
Study on Pembrolizumab, Atezolizumab, and Nivolumab with Carbon Ion Radiotherapy for Patients with Advanced Melanoma, Urothelial Carcinoma, NSCLC, or Head & Neck Cancer
- Disease:Neoplasm
- Substances:AtezolizumabCemiplimab+2
Italy- Participants:18–64 years · 65+ years
- Substances:Atezolizumab
- Sponsor:Fondazione Centro Nazionale Di Adroterapia Oncologica










